THERAPEUTIC APPLICATION OF CHEMICAL ANTIBODIES FOR ANJTIGEN OF DIFFERENTIATION RESTRICTED TO B HUMAN LYMPHOCYTES FOR THE TREATMENT OF CELL LYMPHOMA B.

摘要

Use of an immunologically active chimeric anti-CD20 antibody in the manufacture of a medicament for the treatment of B-cell lymphoma, in which the medicament is for administration to a subject in a unique therapeutically effective dosage of said 100-500 mg antibody / m 2 or in multiple therapeutically effective weekly dosages of said antibody of 100-500 mg / m 2.